Bile, Microbiome, and Metabolic Health

Bile acids are not just soap for dietary fat: they are hormones that talk to your liver, gut, fat and immune cells, and your gut bacteria rewrite them into dozens of variants. That biology is real and important in fatty liver disease and diabetes — but the drugs built on it have mostly disappointed, and nothing bile-specific has been shown to help a healthy person.

For most healthy adults the bile system needs no special treatment: eat a fiber-rich, Mediterranean-style diet, move regularly, keep a healthy weight, go easy on alcohol, and avoid unnecessary antibiotics and acid-blocking pills. Skip "liver detox" and "bile salt" supplements. If you have fatty liver, prediabetes or type 2 diabetes, ask for a FIB-4 score, a free check for liver scarring.

Bile is a hormone system, not just a detergent

The basics are well-established human biochemistry. The liver makes two "primary" bile acids from cholesterol, cholic acid and chenodeoxycholic acid.[1] Stored in the gallbladder and released after meals, they dissolve fat and fat-soluble vitamins — and making them is the body's main way of getting rid of excess cholesterol. Each release also sends a message through two receptors that don't always pull the same way.[2]

FXR (the farnesoid X receptor) sits inside liver and gut cells. When bile acids return to the end of the small intestine, FXR there releases a hormone, FGF19 (fibroblast growth factor 19), that tells the liver to stop making bile acid and damps its glucose and fat production — the system's main brake.[3] Cafestol, an oily compound in unfiltered coffee, is a potent FXR trigger; by slowing the conversion of cholesterol into bile acid it nudges LDL cholesterol up — one reason paper-filtered coffee is gentler on lipids (see Coffee).

TGR5 sits on the surface of gut hormone cells, brown fat, muscle and immune cells. In the gut it releases GLP-1 (glucagon-like peptide-1), the hormone that modern weight-loss drugs mimic;[4] in brown fat and muscle it raises energy burning — but mainly in rodents and human cells.[5] In people the evidence is thin: 12 healthy women taking chenodeoxycholic acid for two days had more active brown fat and burned slightly more energy, but that bile acid also switches on FXR, so TGR5 is not proven to be the route.[6] Studies of natural bile acid levels and brown fat are mixed.[7] There is no approved TGR5 drug: activating it fills the gallbladder in animals, and the one published human trial — six days in 51 adults with type 2 diabetes — gave erratic results, with blood sugar rising at the lowest doses and not falling at the highest.[8]

The two receptors work against each other on GLP-1: TGR5 raises it, gut FXR suppresses it, so "more bile signaling" is not simply better.[9] Nor does this explain why drugs that trap bile acids in the gut, bile acid sequestrants, lower blood sugar: in a 17-day trial in 15 adults with type 2 diabetes, using sevelamer, a phosphate-binding drug that also traps bile acids, blocking GLP-1 did not take the glucose lowering away, and a single dose of colesevelam did not raise GLP-1. GLP-1 looks like a minor part of the story; the main route is unknown.[10][11]

Much of this detail comes from mice, whose bile acids differ from ours.

Your gut bacteria rewrite your bile

Gut bacteria first strip off the glycine or taurine the liver attaches to each bile acid; then a few specialists turn cholic acid into deoxycholic acid and chenodeoxycholic acid into lithocholic acid — the "secondary" bile acids. The genes for that step turn up in most people, but in well under 1% of their gut bacteria.[12] The producers grown in the lab are a few Clostridium species, though gene surveys suggest most belong to a group nobody has yet cultured.[13]

In 2024 the textbook picture was redrawn: the same bacterial enzymes also run in reverse, attaching many different amino acids and other molecules to bile acids. These "microbially conjugated" bile acids reach stool concentrations as high as the classic ones.[14] What they do for health is not yet known; in cell experiments some act on receptors beyond FXR and TGR5.[15]

Since each bile acid acts differently at the receptors, the microbiome sets the system's tone. In germ-free mice, an FXR-blocking bile acid piles up and shuts down the feedback loop — but it is a mouse bile acid humans largely lack.[16] The working idea is that a disturbed microbiome alters bile signaling and feeds insulin resistance, fatty liver, a leakier gut and inflammation: plausible, and mostly mechanistic.

Where it matters for disease

Fatty liver disease. Now called metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), it affects roughly a third of adults worldwide — about 38% in the most recent survey years, and rising — and is tightly linked to type 2 diabetes, heart disease and cirrhosis.[17] The burden is certain; how much bile signaling contributes is moderate, mechanistic and observational evidence.

Type 2 diabetes. Disturbed bile signaling probably contributes too: it shapes the liver's glucose output, and bile-targeted drugs move blood sugar.

Heart disease. Trapping bile acids in the gut makes the liver use up cholesterol and lowers LDL, and one such drug cut heart attacks in a large trial in men (see the drugs section below). Whether bile signaling itself affects heart risk is unclear: cohort studies disagree, linking higher levels of some bile acids to more heart disease in people newly diagnosed with type 2 diabetes but to fewer cardiovascular deaths in people with existing coronary disease.[18][19]

The brain. Bile acids reach the brain and affect inflammation there, but the link to dementia is largely animal and associational.

Colorectal cancer. Deoxycholic acid is suspected of promoting colon cancer, but the human evidence is mixed and observational. A 2025 pooling of small case-control studies found somewhat more deoxycholic acid and several other bile acids in the stool of people with precancerous polyps — but in people with colorectal cancer, deoxycholic acid was not higher; only two primary bile acids were.[20] The causal evidence is in mice: adding bacteria that make deoxycholic acid increased colon tumours, and a strain engineered to lack that step caused fewer than its unmodified version.[21]

Weight-loss surgery: the best human clue, and why it isn't proof

After gastric bypass, bile acids and FGF19 rise,[22] and in one bypass group they rose more in people whose diabetes went into remission, regardless of weight lost.[23] When bypass and gastric banding produced the same 20% weight loss, bile acids more than doubled only after bypass — though the rise did not predict better insulin release or sensitivity.[24]

Randomized trials complicate the story. Two kinds of gastric bypass shifted bile acids in different ways yet improved metabolism about equally.[25] After bypass or sleeve gastrectomy in people with type 2 diabetes, bile acids rose in the first year but were back to baseline by five years, though some patterns still tracked lasting benefit.[26] Bile acids look like one contributor among several, on small, correlational findings.

The drugs: one cautionary tale, and the ones that won

These treat diagnosed disease; none is a longevity tool.

Bile acid sequestrants. In a randomized trial of 3,806 middle-aged men with high cholesterol, cholestyramine cut coronary deaths plus nonfatal heart attacks over about seven years from 8.6% to 7% of men, with no clear effect on deaths from all causes — one decades-old trial, in men only.[27] Colesevelam, approved as an add-on for type 2 diabetes, lowers HbA1c (a measure of average blood sugar) by about half a percentage point on top of standard drugs in pooled randomized trials; it has no heart-outcome trial.[28]

Obeticholic acid, the first FXR-activating drug, won provisional US approval in 2016 for primary biliary cholangitis, a disease of the liver's bile ducts, but the trial meant to confirm a benefit did not: death, transplant or advanced liver disease occurred about equally often on the drug and on placebo, though many placebo patients switched to the drug.[29] The EU revoked its approval in 2024,[30] and the US FDA, which also found excess liver transplants and deaths among trial patients who started with early-stage disease, withdrew it in November 2025.[31] In the inflammatory form of fatty liver disease (steatohepatitis, or MASH) it improved liver scarring on biopsy, but the FDA rejected it twice: a biopsy is not a hard outcome, and the gain was offset by itching, cholesterol rises and liver-injury risk.[32]

Its successors did no better. Newer FXR drugs such as cilofexor and tropifexor cut liver fat in early trials and caused more itching, but never showed any improvement in scarring,[33] and both are no longer being developed for fatty liver; the furthest-along FXR drugs left are only in phase 2.[34] An engineered FGF19, aldafermin, cut liver fat but missed its main scarring target.[35]

The fatty-liver drugs that did win approval don't act on FXR. Resmetirom, a liver-targeted thyroid-hormone mimic, was approved in the US in March 2024 and the EU in August 2025 for steatohepatitis with moderate-to-advanced scarring (not cirrhosis); scarring improved in about 24–26% of patients against 14% on placebo, and LDL fell rather than rose.[36] Semaglutide followed in the US in August 2025 (see GLP-1 agonists).[37] Both were approved early on biopsy improvements — the evidence obeticholic acid was turned down on — and whether they prevent cirrhosis or death is still being tested.

Lithocholic acid and aging: a mouse lead, not a supplement

Lithocholic acid rises in calorie-restricted mice, and in late 2024 it was reported to reproduce several of restriction's benefits in older mice — better muscle repair, grip strength and insulin sensitivity — and to extend lifespan in worms and flies. In mice the lifespan gain was small, and only one of six comparisons, barely, reached statistical significance. A mammalian lifespan effect is not established, and there are no human data.[38]

Do not take it. It is one of the more toxic bile acids: fed to rabbits and monkeys it damages the liver,[39] and in rats, bile acids placed in the colon promoted tumours started by another carcinogen.[40]

What helps, what hurts and what's overhyped

What disrupts the system. A high-saturated-fat, low-fiber diet alters the microbiome and raises the secondary bile acid load; excess alcohol harms the liver and the microbiome. Ultra-processed food is linked to fewer barrier-supporting gut bacteria: in mice, common emulsifiers thin the gut's protective mucus and drive inflammation, while in small, short human trials they shifted gut bacteria and lowered beneficial short-chain fatty acids but did not raise blood markers of gut leakiness or inflammation.[41][42] Long-term use of proton-pump inhibitors (acid-blocking pills) also alters the gut microbiome.

Antibiotics. Some, such as vancomycin, quickly wipe out the bacteria that make secondary bile acids.[43] The microbiome mostly recovers within about six weeks, though a few species can stay missing for six months or more; whether bile acids stay altered that long is unmeasured in people.[44]

Gallbladder removal changes the timing of bile flow without wrecking metabolism. Across seven studies of about 14.6 million people it was linked to roughly 50% higher odds of fatty liver disease — an association likely inflated by the metabolic risk factors behind gallbladder disease, drawn partly from one-time snapshots, and fading in studies with more than ten years of follow-up.[45] For colorectal cancer there is no clear overall increase, though right-sided colon cancer may be about 20% more common — again observational, with shared risk factors.[46]

What supports it is ordinary good eating. Soluble fiber binds bile acids so they leave in the stool, making the liver use cholesterol to replace them — why oats and legumes lower LDL. Polyphenol-rich and fermented foods and a Mediterranean pattern support a diverse microbiome. Protein and choline feed into bile, but there is no evidence that eating more than enough changes bile signaling.

Good habits, but not via bile. An overnight fast is reasonable, but when lean adults ate all their food in one evening meal for 11 days, their bile acids and FGF19 did not change.[47] A single exercise session briefly shifts blood bile acids; whether regular training changes bile signaling is unknown.[48] Bile acid production follows a daily clock — in people it peaks in the daytime and falls overnight, the reverse of rodents — but there is no evidence sleep habits change it.[49]

Overhyped:

  • "Liver detox" supplements such as milk thistle and dandelion root — unproven for a healthy liver; no substitute for fixing the cause.
  • Coffee enemas and "liver flushes" — no benefit and real risks: rectal injury, bowel perforation, electrolyte disturbance.
  • Probiotics sold for "gut healing" — unproven: most lack rigorous evidence for general use; specific strains have specific medical uses.

When to get checked

See a clinician if you have unexplained raised liver enzymes, fatty liver found on a scan, persistent digestive symptoms such as bloating or poorly absorbed fat, or a strong family history of liver disease, gallstones or bile-duct disorders. Tests to discuss:

  • Liver enzymes (ALT, AST, GGT, alkaline phosphatase), a lipid panel, and HbA1c or fasting glucose. Fasting insulin gives an earlier read on insulin resistance (see midlife labs), though liver guidelines do not require it.
  • With signs of poor fat absorption or a bile-duct disorder: vitamin D and a clotting test (INR), which reflects vitamin K status.
  • FIB-4, a free score calculated from age, two liver enzymes and platelet count. It is the recommended first check for liver scarring with fatty liver, prediabetes, type 2 diabetes or two or more metabolic risk factors, repeated every one to two years. Below 1.3 (2.0 over age 65) means low risk; above that, the next step is usually a liver-stiffness scan such as FibroScan or a blood test called ELF. The score is less reliable under age 35.[50]

Gallstones

Gallstones are more likely with female sex, multiple pregnancies, oral contraceptives, hormone replacement therapy, obesity, metabolic syndrome, family history, some ethnic backgrounds (Native American, certain Hispanic) and — paradoxically — rapid weight loss; consistent but observational evidence.

To lower your risk:

  • Lose weight no faster than about 1.5 kg a week; gallstone risk climbs steeply above that rate.[51]
  • Keep some fat in the diet while losing weight. In weight-loss trials, diets with more fat led to far fewer gallstones than very-low-fat ones, probably because fat makes the gallbladder empty regularly — though the trials were few and small and the result did not hold up in a stricter analysis.[52]
  • Coffee modestly lowers the risk of symptomatic gallstones in cohort studies; fiber and a Mediterranean-style diet help too.
  • If you are planning rapid weight loss — bariatric surgery or a very-low-calorie diet — ask your clinician about ursodeoxycholic acid (UDCA), a prescription bile acid. After bariatric surgery, pooled trials found about two-thirds fewer new gallstones, with doses of 500–600 mg a day for 6–12 months effective, though no clear drop in gallbladder removals.[53] Trials in dieters found an even larger effect.[54] But the largest single trial, in 985 people having gastric bypass, found no significant overall reduction in gallstone symptoms; the benefit showed only in those without gallstones before surgery.[55]

Further reading

  • Chen & Gong. Bile acid–microbiota interactions in cardiometabolic diseases (review). Front Microbiol 2025.[56]
  • Li et al. Regulation of bile acids and their receptor FXR in metabolic diseases. Front Nutr 2024.[57]
  • Shi et al. An update on bile acid–regulated signalling in MASLD. Liver Int 2026.[58]
  • Stanimirov et al. Gut–brain axis and bile acid signaling. Int J Mol Sci 2025.[59]
  • Bozadjieva et al. Targeting FXR and FGF19 to treat metabolic diseases — lessons from bariatric surgery. Diabetes 2018.[60]
  • Guzior et al. Bile salt hydrolase acyltransferase activity expands bile acid diversity. Nature 2024.[61]
  • Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984.[62]
  • Ooi & Loke. Colesevelam for type 2 diabetes mellitus (Cochrane review). Diabet Med 2014.[63]
  • Kowdley et al. COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls. Am J Gastroenterol 2025.[64]
  • Younossi et al. Obeticholic acid for NASH — phase 3 REGENERATE interim analysis. Lancet 2019.[65]
  • Harrison et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024.[66]
  • Qu et al. Lithocholic acid phenocopies anti-ageing effects of calorie restriction. Nature 2025.[67]
  • Rinella et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023.[68]
  • Powell et al. Gut microbiome–produced bile acid metabolite lengthens the circadian period. PNAS 2026.[69]

— § —